• This is a political forum that is non-biased/non-partisan and treats every person's position on topics equally. This debate forum is not aligned to any political party. In today's politics, many ideas are split between and even within all the political parties. Often we find ourselves agreeing on one platform but some topics break our mold. We are here to discuss them in a civil political debate. If this is your first visit to our political forums, be sure to check out the RULES. Registering for debate politics is necessary before posting. Register today to participate - it's free!

Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut

JacksinPA

JacksinPA

Supporting Member
DP Veteran
Monthly Donator
Joined
Dec 3, 2017
Messages
26,290
Reaction score
16,771
Gender
Male
Political Leaning
Progressive
nypost.com

Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut

Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market cap…
nypost.com nypost.com

Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.

The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering on Thursday.
==============================================
I think that there is a lot of potential here. Psilocybin has been used in cognitive therapy & ibogaine is used in substance withdrawal.
 
JacksinPA said:
nypost.com

Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut

Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market cap…
nypost.com nypost.com

Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.

The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering on Thursday.
==============================================
I think that there is a lot of potential here. Psilocybin has been used in cognitive therapy & ibogaine is used in substance withdrawal.
Click to expand...
"Psilocybin is a Schedule I substance under the Controlled Substances Act, meaning that it has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision."


How does that impact US distribution? The Schedule 1 list needs a scientist to look at it.
 
mrjurrs said:
"Psilocybin is a Schedule I substance under the Controlled Substances Act, meaning that it has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision."


How does that impact US distribution? The Schedule 1 list needs a scientist to look at it.
Click to expand...

Psilocybin has been on & off in trials since Timothy Leary. In cognitive therapy it aids in vocalization of deep emotions & memories.
 
You must log in or register to reply here.
Back
Top Bottom